Biodesign is a methodology for medical technology innovation which was
founded at Stanford University. It is the most effective methodology in the world
for clinical innovation. At its core is the belief that innovation isn't magic, but
rather a rigirous process that can be learned, practiced and perfected.
In its 20-year history, Biodesign alumni, who are usually complete beginners
to medical technology innovation at the onset, have created 56 successful companies,
impacted over 10 million lives, raised over $1.2B in venture capital and created
over 2,000 jobs, with centers now established across four continents.
In the Biodesign process, innovators first identify the most promising unmet clinical need
to move forward with through an extensive needs finding and screening process, which includes
clinical observation, stakeholder interviews and needs research, followed by
an objective and structured method to filter needs. Innovators then
brainstorm and screen potential solution concepts. The final stage before committing
to a project is the strategy development phase, where innovators
confirm the clinical, technical and operational strategy (including regulatory, reimbursement,
intellectual property and commercialisation strategy).
Learn more about the Biodesign process here.